GREENFIELD, Ind. and
LEAWOOD, Kan., April 25, 2016 /PRNewswire/ -- Elanco Animal
Health, a division of Eli Lilly and Company (NYSE: LLY) and Aratana
Therapeutics, Inc. (NASDAQ: PETX), today announced that Elanco has
licensed animal health rights to Aratana's Galliprant (grapiprant
tablets), an FDA-approved therapeutic for the control of pain and
inflammation associated with osteoarthritis in dogs. The agreement
grants Elanco exclusive rights to develop, manufacture, market, and
commercialize Galliprant globally, and co-promote the product with
Aratana in the United States.
"This deal expands Elanco's robust companion animal portfolio,
which will now give our customers and their patients a spectrum of
treatments for managing osteoarthritic pain," said Jeff Simmons, president of Elanco Animal
Health."At Elanco, we understand the powerful role healthy animals
play in making life better. As pets become important parts of our
families, the need to help them live longer, healthier, higher
quality lives increases as well."
The most common type of arthritis in dogs, osteoarthritis
affects up to 20 percent of the adult canine
population.1 Osteoarthritis can result when joint
cartilage - the protective material that cushions and allows smooth
movement in a joint – becomes thin and breaks down over time,
leading to pain and inflammation in the joint. The frequent result
is stiffness and a reluctance to run, jump, or even climb
steps.
"Aratana understands the value of relationships with the right
collaborators," said Steven St.
Peter, M.D., President and Chief Executive Officer of
Aratana Therapeutics. "We believe that this collaboration with
Elanco, a leading animal health company, is a watershed event for
the emerging pet biotech sector and further validates our focus on
the pet therapeutics opportunity."
Under the terms of the agreement, Aratana will receive an
upfront payment of $45 million,
additional payments upon achievement of certain development,
regulatory and sales milestones up to $83
million, and co-promotion fees and royalty payments.
Contacts:
For Elanco inquires:
Keri McGrath Happe
Communications Manager
Elanco Animal Health
T: +1-317-370-8394
E: mcgrath_happeks@elanco.com
For Aratana inquires:
Craig
Tooman
Aratana Therapeutics, Inc.
ctooman@aratana.com
(913) 353-1026
Important Safety
Information
GALLIPRANT® (grapiprant
tablets) is for use in dogs only. Do not use in dogs younger than 9
months of age and less than 8 lbs (3.6 kg), dogs used for breeding,
or in pregnant or lactating dogs. Adverse reactions in dogs may
include mild gastrointestinal effects including, vomiting, diarrhea
and decreased appetite. Should not be used in dogs that have a
hypersensitivity to grapiprant. If used long term, appropriate
monitoring is recommended. Avoid use with COX-inhibiting NSAIDs or
corticosteroids. Please see the full Prescribing Information.
ABOUT ELANCO
Elanco, a division of Eli Lilly and
Company, provides comprehensive products and knowledge services to
improve animal health and food-animal production in more than 70
countries around the world. With a global presence of approximately
7,000 people and offices in more than 40 countries, Elanco
anticipates, serves and supports the diverse and evolving needs of
its customers--from veterinarians to food producers to all those
concerned with animal health--to help them address the challenges
of a diverse and changing world. Together with our customers, we
are committed to raising awareness about global food security, and
celebrating and supporting the human-animal bond. Additional
information about Elanco is available at www.elanco.com, or follow
us @Elanco.
ABOUT ARATANA THERAPEUTICS
Aratana Therapeutics is a
pet therapeutics company focused on licensing, developing and
commercializing innovative pharmaceutical products for dogs and
cats. Aratana believes that it can leverage the investment in the
human pharmaceutical industry to bring therapeutics to pets in a
capital and time efficient manner. The Company has multiple
products approved by the Food and Drug Administration's Center for
Veterinary Medicine or licensed by the United States Department of
Agriculture. The Company's pipeline includes therapeutic candidates
targeting pain, inappetence, cancer, viral diseases, allergy and
other serious, unmet or underserved medical needs. Aratana
believes providing innovative options to veterinarians and pet
owners will help manage pets' medical needs safely and effectively,
resulting in longer and improved quality of life for pets. For more
information, please visit www.aratana.com.
This press release contains forward-looking statements (as
that term is defined in the Private Securities Litigation Reform
Act of 1995) about the collaboration between Aratana and
Elanco, and reflects Lilly, Elanco's and Aratana's current beliefs.
However, as with any pharmaceutical product, there
are substantial risks and uncertainties in the process of
development and commercialization. Among other things, there
can be no guarantee that the research collaboration will
yield successful results, that either company will achieve the
anticipated benefits or that the results will be commercially
successful. For further discussion of these and other risks
and uncertainties, see Lilly's and Aratana's most recent Form 10-K
and Form 10-Q filings with the United States Securities and
Exchange Commission, respectively. Except as required by law,
Elanco and Aratana undertakes no duty to update forward-looking
statements to reflect events after the date of this
release.
1 JAVMA, Vol 236, No. 1, January 1, 2010 p 59-66
Logo -
http://photos.prnewswire.com/prnh/20160425/359503LOGO
Logo -
http://photos.prnewswire.com/prnh/20160425/359502LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/aratana-elanco-announce-global-strategic-collaboration-300256859.html
SOURCE Aratana Therapeutics, Inc.; Elanco Animal Health